Arthralgia in South Indian patients with pulmonary tuberculosis during treatment with pyrazinamide and rifampicin by Nazareth, O et al.
231
ARTHRALGIA IN SOUTH INDIAN PATIENTS WITH
PULMONARY TUBERCULOSIS DURING TREATMENT WITH
PYRAZINAMIDE AND RIFAMPICIN
NAZARETH, O., ACHARYULU, G. S., JANARDHANAM, B., KRISHNAMURTHY, P.V.,
PARTHASARATHY, R., PREMA DEVADATTA, RAGHUPATI SARMA, G.
RANI BALASUBRAMANIAN, RAMAKRISHNAN, C. V.,
SANTHA T., AND TRIPATHY, S. P.,
Tuberculosis Research Centre (Indian Council of Medical Research), Madras-600 031, India
(Received for publication. May 1984)
ABSTRACT
Arthralgia was the major adverse reaction encountered in a clinical trial of the treatment
of pulmonary tuberculosis with three short-course regimens containing pyrazinamide in South
Indian patients. The first regimen was of rifampicin, streptomycin, isoniazid and pyrazinamide
given daily for three months; the second was of the same four drugs daily for three months
followed by streptomycin, isoniazid and pyrazinamide twice-weekly for two months, and the
third was the same as the second except that rifampicin was not administered. Arthralgia
was reported in 36% of 353 rifampicin patients and 66% of 179 non-rifampicin patients, a highly
significant difference (p<0.001). The onset of arthralgia was mostly during the first two
months of chemotherapy. The knees were affected in about 90% followed by the ankles in
about 50% of the patients with arthralgia, and about 60% of these patients had one or more
of the signs, swelling, tenderness and limitation of joint movement. Chemotherapy was
modified in 10 rifampicin and 15 non-rifampicin patients; the rest of the patients were managed
with symptomatic treatment with analgesics. There was a two to three fold increase in serum
uric acid concentrations by the end of the first month and the concentrations were more or
less stationary throughout the rest of the daily phase of treatment. The mean concentration
during the daily phase of treatment in patients with arthralgia (0.482 mmoles/litre) was similar
to that in those without arthralgia (0.484 mmoles/litre), while that in the rifampicin patients
(0.476 mmoles/litre) was significantly lower (p=0.03) than that in the non-rifampicin patients
(0.495 mmoles/litre).
Introduction
Arthralgia is a common adverse reaction associated
with daily pyrazinamide therapy, especially in South
Indian patients (Velu et al, 19611, 19642, lyer and
Srinivasan, 19783, Tuberculosis Research Centre,
Madras, 19834). This adverse reaction is probably
due to the deposition of uric acid in joints caused by
hyperuricaemia resulting from an inhibition of the
excretion of uric acid by pyrazinoic acid (Cullen et al,
19565, Yu et al, 19576, Weiner and Tinker, 19727,
Fanelli and Weiner, 19738, Ellard and Haslam, 19769).
a major metabolite of the drug (Weiner and Tinker,
19727, Ellard, 19691o). Two controlled clinical trials
of the treatment of pulmonary tuberculosis with short-
course regimens were undertaken in the Centre; the
findings of arthralgia during therapy in the first trial
were reported earlier (Tuberculosis Research Centre,
Madras, 19834). More detailed observations were
made during the second trial (Tripathy, 198211) and
the findings are now presented.
Materials and Methods
Treatment regimens:Patients with sputum posi-
tive pulmonary tuberculosis were allocated at random
to one of the following regimens:
R3: Rifampicin plus streptomycin plus isoniazid
plus pyrazinamide daily for three months.
R5: The same as R3 followed by streptomycin,
isoniazid and pyrazinamide twice-weekly for two
months.
Z5: The same as the R5 regimen, but without
rifampicin.
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The dosages of the drugs during the daily phase
were rifampicin 12 mg/kg body-weight, streptomycin
0.75 g, isoniazid 400 mg and pyrazinamide 35 mg/kg;
the dosages during the twice-weekly phase were
streptomycin 0.75 g, isoniazid 15 mg/kg and
pyrazinamide 70 mg/kg.
The patients were not questioned to elicit symptoms
of any adverse reactions, but any spontaneous com-
plaint by the patient was followed by careful question-
ing by a physician, who recorded the full details.
Serum uric acid concentrations
Serum uric acid concentrations were determined by
a phosphotungstate reduction method (Henry t al,
195712) before the start of treatment, and at monthly
intervals till the end of treatment.The determinations
were undertaken approximately 24 hours after the
previous dose of drugs during the daily phase, and
72-96 hours during the twice-weekly phase.
Results
 In all, 532 patients were admitted to the study (173
R3, 180 R5, and 179 Z5). The incidence and the
time of onset of arthralgia in these patients are presented
in Table-l.
TABLE–1
ONSET OF ARTHRALGIA DURING
TREATMENT
Occurrence of arthralgia at the
Total Patients following months
Regimen No. of with
patients arthralgia 4-5
1 2 3  ( T w i c e -
(Daily phase) weekly
phase)
No. % No. % No. % No. % No. %
R3 173 67 3 9 25 14 38 22 3 2 1* 1
R5 180 66 37 17 9 40 22 5 3 4 2
R 3 + R 5 353   133   38   42   12   78   22 8 2 5 1
Z5 179 118 66 49 27 60 34 7 4 2 1
‘This patient first complained of arthralgia in the 15th week.
In the great majority of the patients with arthralgia,
the onset occurred during the initial daily phase during
which the two rifampicin regimens were identical and
the results, which were also similar, have been amal-
gamated subsequently. The proportions of patients
who complained of arthralgia were 38% of 353 rifam-
picin patients and 66% of 179 non-rifampicin patients,
a highly significant difference (p<0.001). Most of
the cases occurred in the first two months, particularly
the second, and there were hardly any during the
third month or the subsequent twice-weekly phase.
The proportions of the 133 rifampicin patients with
arthralgia during the first nine weeks and beyond were
2%, 5%, 6%, 13%, 12%, 19%, 14%, 11%, 9% and 9%,
respectively; the proportions of the 118 non-rifam-
picin patients were 3%, 4%, 7%, 20%, 22%, 18%,
12%, 3%, 5% and 6%, respectively. The over-all
proportions in the two groups were similar during the
first three weeks, higher in the non-rifampicin patients
during the period four to six weeks, and higher in the
rifampicin patients during the last three weeks.
Joints involved: The joints most frequently affected
(Table–2) were of the lower limbs, the knees being
involved in over 90%. the ankles in about 50% and
the feet and hips in about 15-20% of the patients.
TABLE-2
JOINTS INVOLVED IN ARTHRALGIA
Regimen
Joints
R3 + R5 Z5
NO. % No. %
Shoulders 15 11 17
Elbows 22 17 17
Wrists 26 20 38
Hands 32 24 46
Hips 20 15 19
Knees 123 92 112
Ankles 58 44 62
Feet 23 17 23
Vertebrae 2 2 3
14
14
32
39
16
95
53
19
3
No. of patients with
arthralgia
133 118
The upper limbs were less frequently involved,
the order of frequency being the hands, the
wrists, the elbows and the shoulders, and vertebral
involvement was rare. Only one type of joint was
affected in 36% of the 133 rifampicin patients and
25% of the 118 non-rifampicin patients, two types of
joints were involved in 28% and 29%. and three or
more in 36% and 47%. respectively.The joint invol-
vement was bilaterally symmetrical in a great majority
of the patients (nearly 98%) in both groups.One
or more large joints were affected in 90% of the rifam-
picin patients and in all the non-rifampicin patients.
There was a suggestion that small joints were more
frequently affected in the non-rifampicin patients than
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in the rifampicin patients, the proportions
and 32%. respectively (p=0.03).
being 46%
Symptoms and signs: In addition tojoint pain,
joint swelling was observed in 36% of the rifampicin
patients and 47% of the non-rifampicin patients, joint
tenderness in 32% and 42%, and limitation of move-
ment in 30% and 36%, respectively.Of the rifampicin
patients with arthralgia, 40% had pain only, 33% had
one sign in addition, 16% had two signs and 11% had
three signs; the corresponding proportions in the non-
rifampicin patients were 37%, 25%, 13% and 25%.
respectively. The proportion of patients with pain
plus three signs was lower in the rifampicin patients
than in the non-rifampicin patients (p<0.01).
butazone, phenylbutazone or ibuprofen (300 mg/day),
either singly or in combination.The mean duration
of treatment with analgesics was 22 days in the
rifampicin patients and 26 days in the non-rifampicin
patients. A combination of two analgesics to
relieve symptoms was used in 18% of the rifampicin
and 30% of the non-rifampicin patients (p=0.03);
however, the mean duration of such treatment was
11 days in the former and seven days in the latter
(p=0.04).
Serum uric acid concentrations: Since the onset
of arthralgia was mainly during the daily phase and
since rifampicin was also administered only during this
phase, comparisons were made of uric acid concentra-
tions on admission and during the daily phase of
treatment (Table-4.)Management of arthralgia:Details of the manage-
ment of arthralgia in patients are presented in Table-3.
TABLE-3
MANAGEMENT OF ARTHRALGIA
Action taken
Regimen
R3 + R5 Z5
No. % No. %
Modi f i cat ion  o f  chemotherapy*
Interruption
Reduction of dosage
Interruption + reduction
Termination
Total
Analgesics administered
Aspirin
Oxyphenylbutazone
Phenylbutazone
Ibuprofen
Others
3 2
1 1
1 1
5 4
10 8
95 71
80 60
32 24
19 14
23 17
9 8
0 0
4 3
2 2
15 13
77 65
96 81
36 31
22 19
35 30
No. of patients with arthralgia 133 118
*With respect to pyrazinamide administration
The mean duration of arthralgia was 47 days in
the rifampicin patients and 54 days in the non-rifam-
picin patients. It was only in a small proportion of
the patients, namely in 10 of 133 rifampicin patients
and 15 of 118 non-rifampicin patients that chemo-
therapy was modified through interruption, reduction
or termination of pyrazinamide.In the rest of the
patients, arthralgia was managed mainly by the use
of analgesics such as aspirin (1.8 g/day), oxyphenyl-
TABLE-4
MEAN SERUM URIC ACID CONCENTRATIONS
BEFORE AND DURING DAILY TREATMENT
Mean ± S.D. serum uric acid
concentrations (mmoles/l)
Group Total
patients Before
treatment
During daily
treatment*
Arthralgiaa 237 0.184 ± 0.062 0.482 ± 0.137
No arthralgiaa 247 0.197 ± 0.073 0.484 ± 0.134
Rifampicinb 319 0.193 ± 0.071 0.476 ± 0.136
No rifampicinb 165 0.187 ± 0.062 0.495 ± 0.133
*Mean of determinations at 1, 2 and 3 months
aAmalgamating patients in the rifampicin and the non-rifampicin
groups
bAmalgamating patients with and without arthralgia
The mean values at one, two and three months
within each group were similar, the mean concentra-
tions being 0.472, 0.467 and 0.488 mmoles/litre,
respectively in the rifampicin patients, and 0.497,
0.490 and 0.497 mmoles/litre, in the non-rifampicin
patients; the mean of the three values was therefore
taken for subsequent analysis.
There was a two to three fold increase in the serum
uric acid concentration during daily treatment with
pyrazinamide with or without rifampicin. The dif-
ferences between the mean concentrations during
treatment in patients with and without arthralgia and
for those in the rifampicin and the non-rifampicin
groups were tested after adjusting for pre-treatment
differences in serum uric acid concentrations (by
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analysis of co-variance). It was observed that the
difference in the mean concentrations between
patients with and without arthralgia was not signi-
ficant (p>0.2); however, the mean concentration in
the rifampicin group was significantly lower (p=0.03)
than that in the non-rifampicin group.
Of the 247 patients without arthralgia at any time
(included in the serum uric acid analysis), 194 be-
longed to the rifampicin group and 53 to the non-
rifampicin group; the mean serum uric acid concen-
trations during the daily phase of treatment in these two
groups were 0.476 and 0.510 mmoles/litre, respec-
tively (p=0.03). Of the 237 patients who had
complained of arthralgia, the corresponding mean
values in 125 rifampicin and 112 non-rifampicin
patients were 0.476 and 0.488 mmoles/litre, res-
pectively (p > 0.2).
The mean serum uric acid concentrations during
the twice-weekly phase (not tabulated) were similar
in patients with and without arthralgia. and for those
in the rifampicin and the non-rifampicin groups, and
have been amalgamated; the mean values at four and
five months were 0.293 and 0.279 mmoles/litre, res-
pectively. These concentrations, though significantly
higher than the pretreatment values (p<0.001), are
well within normal limits (0.090 to 0.420 mmoles/
litre), and appreciably lower than those during daily
treatment (p<0.001).
Discussion
The incidence of arthralgia in Madras patients on
pyrazinamide regimens is high, 38% of 353 rifampicin
and 66% of 179 non-rifampicin patients having com-
plained of arthralgia during treatment.It is, therefore,
evident that concomitant administration of rifam-
picin appreciably decreases the incidence of arthral-
gia. This confirms the findings of an earlier study
undertaken at this Centre with short-course regimens
containing streptomycin, isoniazid and pyrazinamide
with or without rifampicin (Tuberculosis Research
Centre, Madras, 19834) where the incidence of
arthralgia was 24% of 338 rifampicin patients and
46% of 345 non-rifampicin patients. The arthralgia-
sparing effect of rifampicin was also observed by
Sharma and others in Jaipur patients where the over-
all incidence of arthralgia was 16-19% (Sharma et al.
198113, 198314), but not observed in Hong Kong
patients where the incidence was low (Jenner et al,
198115, Hong Kong Tuberculosis Treatment Services/
British Medical Research Council, 197616).
In the present study, in addition to joint pain, about
60% of patients with arthralgia had one or more of
the signs, swelling, tenderness and/or limitation of
joint movement. The proportion of patients having
all three signs was significantly less in the rifampicin
patients, suggesting that rifampicin also decreased
the severity of arthralgia.
The onset of arthralgia in most of the patients was
during the daily phase, particularly during the first
two months, and daily treatment for an additional
month did not result in an increase in the incidence;
the onset during the intermittent phase was also low
Even though the incidence of arthralgia was high
in our patients, modification of treatment such as
interruption, reduction of dosage or termination of
pyrazinamide was taken in only a small proportion
of the patients, namely in 8% of the rifampicin and
13% of the non-rifampicin patients.The other patients
with arthralgia continued their normal activities with
symptomatic treatment with analgesics such as aspirin
(1.8 g/day), oxyphenylbutazone, phenylbutazone or
ibuprofen (300 mg/day).
Perusal of serum uric acid concentrations in the
individual patients indicated that daily treatment
with pyrazinamide, with or without rifampicin, resulted
in a two to three fold increase in serum uric acid con-
centrations, and the values at one, two and three months
were very similar. This suggests that serum is
saturated at this concentration (approximately 0.48-
0.50 mmoles/litre) and the retained uric acid is
probably deposited in the joints leading to arthralgia.
Susceptibility to arthralgia might, however, depend
upon certain other factors such as the concentration
of the urate-binding protein in the individual patients.
No association was observed between arthralgia
and serum uric acid concentrations determined approxi-
mately 24 hours after drug administration-a finding
similar to that reported earlier from this Centre (Tuber-
culosis Research Centre, Madras, 19834) and by other
investigators (Jenner et al 1981 15, Horsfall et al,
197917). It has been demonstrated that the rate of
urinary excretion of uric acid returns to pretreatment
levels by about 24 hours after a dose of pyrazinamide
35 mg/kg (Raghupati Sarma et al, 198318); this, how-
ever, is not reflected in the serum concentrations
possibly on account of the dynamic equilibrium exist-
ing between the serum levels and the deposited uric
acid. Serum concentrations would return to normal
only after the tissue deposits are mobilized and
depleted.
Administration of rifampicin has caused an appre-
ciable decrease in the incidence of arthralgia, the
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mean serum uric acid concentrations during the daily
phase of treatment being slightly, but significantly
less in patients receiving rifampicin, confirming
findings of an earlier study in our Centre (Tuber-
culosis Research Centre, Madras, 19834). In that
study the mean serum uric acid concentrations
before and at the end of daily treatment (two months)
in 324 rifampicin patients were 0.185 and 0.461
mmoles/litre, and those in 333 non-rifampicin patients
were 0.177 and 0.482 mmoles/litre, respectively;
the difference in the mean concentrations at the end
of the daily phase of treatment between the two
groups (after adjusting for pre-treatment differences
in serum uric acid concentrations) was significant
(p=0.02). The slight difference observed in both
studies is probably due to the effect of rifampicin in
enhancing the urinary excretion of both uric acid
(by about 25%) and pyrazinoic acid (by about 16%)
(Raghupati Sarma et al, 198318). This could lead
to a lower deposition of uric acid in joints with conse-
quent lowering of arthralgia in patients receiving this
drug.
The joints most frequently affected during pyra-
zinamide arthralgia in South Indian patients are large
weight-bearing joints nearly always the knees and
frequently the ankles. In Hong Kong patients with
arthralgia during pyrazinamide treatment, the large
joints were also more frequently affected than the
small ones; however, the joint most commonly affected
(72%) were the shoulders (Horsfall et al, 197917).
In both studies, the involvement of small joints was
infrequent and there was simultaneous involvement
of two or more types of joints in about 60-70% of
the patients. In contrast, in gout, which is another
metabolic disorder caused by high levels of circu-
lating uric acid, the joints most commonly affected
are the small ones like the toes (76%). and simul-
taneous involvement of two or more joints (11%)
is uncommon (Grahame and Scott, 197019). There is
only circumstantial evidence to implicate hyperuri-
caemia in arthralgia during pyrazinamide therapy and
as pointed out by Horsfall and others (197917), on
account of the differences in the types of joints
affected between pyrazinamide arthralgia and gout,
it is possible that different mechanisms may be
operative in the two disorders.
Studies carried out in certain other parts of India
and in other countries show an interesting geographical
variation in the incidence of pyrazinamide arthralgia.
Thus, in South India the incidence is high, 67% of
45 patients from Trivandrum (lyer and Srinivasan,
19763), and 61% of 376 patients in Bangalore (un-
published findings) had arthralgia.In Madras
patients, Velu and others in two retreatment studies
(19611, 19642) with pyrazinamide-containing regi-
mens have reported an incidence of 24% in 103
patients. In an earlier short-course regimen study
undertaken at this Centre (Tuberculosis Research
Centre, Madras. 19834), the incidence was 24% of
338 rifampicin patients and 46% of 345 non-rifampicin
patients; in the present report, 38% of 353 rifampicin
patients and 66% of 179 non-rifampicin patients
complained of arthralgia. In North India, the pro-
portions have been reported to be 10% of 146 patients
in Agra (Mehrotra et al, 198120), 13% of 60 patients
in Delhi (Tuberculosis Association of India, 198021),
and 16-19% of a total of 307 patients in Jaipur
(Sharma et al. 198113, 198314). In Hong Kong 7%
of 174 patients (Hong Kong Tuberculosis Treatment
Services/British Medical Research Council, 197616),
in Singapore 4% of 397 patients (Singapore Tuber-
culosis Service/British Medical Research Council,
198122), in East Africa 1% of 693 patients (East
African/British Medical Research Councils Study,
198123) and in Poland none of 119 patients (Zierski
and Bek, 198024) complained of arthralgia during
pyrazinamide therapy. In Britain, of a total of 334
patients (approximately a fifth of whom were probably
of Indian subcontinent origin) who received pyra-
zinamide daily for two months, arthralgia occurred
in only two patients, one of whom was probably of
subcontinent origin (British Thoracic Association,
198125). It is unlikely that subjective errors in the
diagnosis of arthralgia could entirely account for the
large geographical variation observed. Whether this
variation is due to genetic, nutritional or some other
factors remains to be determined.
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